CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

205580Orig1s000

OTHER REVIEW(S)



MEMORANDUM

REVIEW OF REVISED LABEL AND LABELING

Division of Medication Error Prevention and Analysis (DMEPA)

Office of Medication Error Prevention and Risk Management (OMEPRM)

Office of Surveillance and Epidemiology (OSE)

Center for Drug Evaluation and Research (CDER)

Date of This Memorandum: March 30, 2018

Requesting Office or Division: Division of Hematology Products (DHP)

Application Type and Number: NDA 205580

Product Name and Strength: Bendamustine Hydrochloride Injection, 100 mg/4 mL (25

mg/mL)

Applicant/Sponsor Name: Eagle Pharmaceuticals

FDA Received Date: March 20, 2018

OSE RCM #: 2018-283-1

DMEPA Safety Evaluator: Nicole Garrison, PharmD, BCPS

DMEPA Team Leader: Hina Mehta, PharmD

1 PURPOSE OF MEMORANDUM

The Division of Hematology Products (DHP) requested that we review the revised container labels and carton labeling for Bendamustine Hydrochloride (Appendix A) to determine if it is acceptable from a medication error perspective. The revisions are in response to recommendations that we made during a previous label and labeling review.^a We note per email response; the Applicant intends to market the product with the established name, bendamustine hydrochloride for now^b.

2 CONCLUSION


The revised container labels and carton labeling are acceptable from a medication error perspective.

^b Information Request Response received on March 30, 2018.



^a Garrison N. Label and Labeling Review for Bendamustine Hydrochloride (NDA 205580). Silver Spring (MD): FDA, CDER, OSE, DMEPA (US); 2018 MAR 13. RCM No.: 2018-283.

APPENDIX A. IMAGES OF LABEL AND LABELING RECEIVED ON MARCH 20, 2018



3 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page



| This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. |
|---|
| /s/ |
| NICOLE B GARRISON 03/30/2018 |
| HINA S MEHTA 03/30/2018 |

MEMORANDUM

REVIEW OF REVISED LABEL AND LABELING

Division of Medication Error Prevention and Analysis (DMEPA)

Office of Medication Error Prevention and Risk Management (OMEPRM)

Office of Surveillance and Epidemiology (OSE)

Center for Drug Evaluation and Research (CDER)

Date of This Memorandum: March 13, 2018

Requesting Office or Division: Division of Hematology Products (DHP)

Application Type and Number: NDA 205580

Product Name and Strength: Belrapzo (bendamustine hydrochloride) Injection, 100

mg/4 mL (25 mg/mL)

Applicant/Sponsor Name: Eagle Pharmaceuticals

FDA Received Date: January 31, 2018 and February 9, 2018

OSE RCM #: 2018-283

DMEPA Safety Evaluator: Nicole Garrison, PharmD, BCPS

DMEPA Team Leader: Hina Mehta, PharmD

DMEPA Associate Director

(Acting):

Mishale Mistry, PharmD, MPH

1 PURPOSE OF MEMO

The Division of Hematology Products (DHP) requested that we review the proposed container label, carton labeling, and Prescribing Information (PI) for Bendamustine Injection (NDA 205580) for areas of vulnerability that may lead to medication errors (Appendix A). DHP requested this review as a part of their evaluation of the 505(b)(2) NDA class I resubmission for Bendamustine Injection. DMEPA provided recommendations during a previous label and labeling review.^{a,b}

1.1 REGULATORY HISTORY

^b Gao. T. Label, Labeling Review Memo for Bendamustine (NDA 205580). Silver Spring (MD): FDA, CDER, OSE, DMEPA (US); 2014 APR 09. RCM No.: 2013-1791.



^a Gao. T. Label, Labeling and Packaging Review for Bendamustine (NDA 205580). Silver Spring (MD): FDA, CDER, OSE, DMEPA (US); 2013 DEC 24. RCM No.: 2013-1791.

DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

